These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 6247888)

  • 1. Evaluation of prostaglandin and prostacyclin antagonism at platelet receptors by aggregometry.
    Eggerman TL; Harker LA; Andersen NH; Wilson CH
    Adv Prostaglandin Thromboxane Res; 1980; 6():389-93. PubMed ID: 6247888
    [No Abstract]   [Full Text] [Related]  

  • 2. Receptors and receptor mechanisms of endogenous platelet stimulatory and inhibitory mediators.
    MacIntyre DE; Bushfield M; MacMillan LJ; Moffat KJ; Murdoch FA; Thomson A; Rossi AG; McNicol A
    Agents Actions Suppl; 1986; 20():45-62. PubMed ID: 3028106
    [No Abstract]   [Full Text] [Related]  

  • 3. Prostaglandins E1 and E2, but neither prostacyclin nor prostaglandin D2 have anti-aggregating activity in chicken blood.
    Bult H; Wechsung E; Houvenaghel A; Herman AG
    Arch Int Pharmacodyn Ther; 1981 Feb; 249(2):306-8. PubMed ID: 7013724
    [No Abstract]   [Full Text] [Related]  

  • 4. The antagonism of prostaglandins I2, E1 and D2 by prostaglandin E2 in human platelets.
    Bonne C; Martin B; Watada M; Regnault F
    Thromb Res; 1981 Jan 1-15; 21(1-2):13-22. PubMed ID: 6262942
    [No Abstract]   [Full Text] [Related]  

  • 5. Biochemical and pharmacological evaluation of thromboxane synthetase inhibitors.
    Gorman RR
    Adv Prostaglandin Thromboxane Res; 1980; 6():417-25. PubMed ID: 6247892
    [No Abstract]   [Full Text] [Related]  

  • 6. On the multiplicity of platelet prostaglandin receptors. I. Evaluation of competitive antagonism by aggregometry.
    Andersen NH; Eggerman TL; Harker LA; Wilson CH; De B
    Prostaglandins; 1980 May; 19(5):711-35. PubMed ID: 6252573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discrimination between platelet prostaglandin receptors with a specific antagonist of bisenoic prostaglandins.
    MacIntyre DE; Gordon JL
    Thromb Res; 1977 Dec; 11(6):705-13. PubMed ID: 203057
    [No Abstract]   [Full Text] [Related]  

  • 8. Evidence for distinct prostaglandin I2 and D2 receptors in human platelets.
    Miller OV; Gorman RR
    J Pharmacol Exp Ther; 1979 Jul; 210(1):134-40. PubMed ID: 221643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the platelet prostaglandin D2 receptor. Loss of prostaglandin D2 receptors in platelets of patients with myeloproliferative disorders.
    Cooper B; Ahern D
    J Clin Invest; 1979 Aug; 64(2):586-90. PubMed ID: 222813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influences of prostaglandins on electrophoretic mobility and aggregation of rabbit platelets.
    Takano S; Itagaki S; Sakurai K; Suzuki T
    Prostaglandins; 1980 Sep; 20(3):579-86. PubMed ID: 6999547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Refractoriness of platelets to prostaglandins after infusion in rabbits.
    Bertelé V; Stemerman M; Schafer A; Adelman B; Smith M; Fuhro R; Salzman E
    J Lab Clin Med; 1985 Nov; 106(5):551-61. PubMed ID: 2997353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective antagonism of prostaglandin (PG) E1, PGD2 and prostacyclin (PGI2) on human and rabbit platelets by di-4-phloretin phosphate (DPP).
    Westwick J; Webb H
    Thromb Res; 1978 Jun; 12(6):973-8. PubMed ID: 358484
    [No Abstract]   [Full Text] [Related]  

  • 13. Heparin opposes prostanoid and non-prostanoid platelet inhibitors by direct enhancement of aggregation.
    MacIntyre DE; Handin RI; Rosenberg R; Salzman EW
    Thromb Res; 1981 Apr 1-15; 22(1-2):167-75. PubMed ID: 6270842
    [No Abstract]   [Full Text] [Related]  

  • 14. Heparin does not interfere with prostacyclin and prostaglandin D2 binding to platelets.
    Fortini A; Modesti PA; Abbate R; Gensini GF; Neri Serneri GG
    Thromb Res; 1985 Nov; 40(3):319-28. PubMed ID: 3001968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specificity between the anti-aggregatory actions of prostacyclin, prostaglandin E1 and D2 on platelets.
    Whittle BJ; Hamid S; Lidbury P; Rosam AC
    Adv Exp Med Biol; 1985; 192():109-25. PubMed ID: 2871707
    [No Abstract]   [Full Text] [Related]  

  • 16. The antiaggregatory effectiveness of PGI2 and its binding to specific platelet receptors. A comparative study.
    Jaschonek K; Renn W; Weisenberger H
    Prog Clin Biol Res; 1987; 242():13-8. PubMed ID: 3313410
    [No Abstract]   [Full Text] [Related]  

  • 17. Prostacyclin-sensitive adenylate cyclase and prostacyclin binding sites in platelets and smooth muscle cells.
    Nicosia S; Oliva D; Bernini F; Fumagalli R
    Adv Cyclic Nucleotide Protein Phosphorylation Res; 1984; 17():593-9. PubMed ID: 6328938
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of prostaglandin I2 and analogs on platelet aggregation and smooth muscle contraction.
    Crane BH; Maish TL; Maddox YT; Corey EJ; Székely I; Ramwell PW
    J Pharmacol Exp Ther; 1978 Jul; 206(1):132-8. PubMed ID: 351171
    [No Abstract]   [Full Text] [Related]  

  • 19. The effect of prostacyclin (PGT2) on platelet behaviour. Thrombus formation in vivo and bleeding time.
    Ubatuba FB; Moncada S; Vane JR
    Thromb Haemost; 1979 Apr; 41(2):425-35. PubMed ID: 382434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostaglandin receptors on human platelets. Structure-activity relationships of stimulatory prostaglandins.
    MacIntyre DE; Salzman EW; Gordon JL
    Biochem J; 1978 Sep; 174(3):921-9. PubMed ID: 215124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.